



**Vision**  Global Top Tier Biohealth Company

**Mission**  Heal the World for Better Life

**Key Milestones** 



**Manufacturing Facilities** 



**Plant 1 (Osong, Korea)**

|               |  |
|---------------|--|
| Plant Area    | 146,013 m <sup>2</sup>   |
| Built up Area | 24,562 m <sup>2</sup>  |
| Main Products | Oncology (Irinotecan, Pemetrexed RTU)<br>CV(Amlodipine, Ramipril)<br>Endo (Glimepiride)<br>GI(Rabeprazole) |



**Plant 2 (Daeso, Korea)**

|               |   |
|---------------|---|
| Plant Area    | 42,829 m <sup>2</sup>                                       |
| Built up Area | 8,337 m <sup>2</sup>  |
| Main Products | IV Soln., TPN<br>Oral API<br>Cephalosporin (API & Finished) |



**Plant 3 (Icheon, Korea)**

|               |                             |
|---------------|-----------------------------|
| Plant Area    | 169,679 m <sup>2</sup>      |
| Built up Area | 46,532 m <sup>2</sup>       |
| Main Products | Biologics (EPO)<br>Vaccines |

HK inno.N Corp.  
**Introduction**

**HK inno.N Corp. Korea (Headquarter)**

Pine Avenue A, 100 Eulji Road, Jung-gu, Seoul 04551, Korea  
T : +82-2-6477-0000 F : +82-2-6477-0697 E : hkin\_business@inno-n.com

**Hankol HealthCare Vina, Vietnam**

Unit 0921, Level 9, CJ Building, bis-4-6 Le Thanh Ton, Ben Nghe Ward, Dist.1, HCMC, Vietnam  
T : +84-28-6255-6738 E : minki.ku@inno-n.com

**HK inno.N Corp. Japan Office**

8th fl. Of CJ Bldg. Nishishinbashi 2-7-4, Minato-ku, Tokyo 105-0003 Japan  
T : +81-80-1249-0427 E : sungbin.cho@inno-n.com



## Manufacturing sites



### OSONG Plant

- Quality Management System for high-quality products
- Cutting-edge production infrastructure (Facilities & IT system)
- Technical skills and hands-on experience for over 30 years



#### Oral Solid Dosage Forms

- Three identical granulation lines with 30/100/300 Kg capacities
- 2 billion tablets and 1 billion capsules per year

#### Cytotoxic Oncology Injectables

- Building dedicated to cytotoxic injectables
- Closed Restricted Access Barrier System technology

### DAESO Plant

- 20 years of Sterile antibiotics experience
- 20 years of CMO experience with Japanese original pharmaceutical companies
- High-quality API/FDF manufacturing techniques
- Global inspection know-how
- GMP upgrade production facility to meet PIC/s guidelines



#### Parenteral Products

- IV solution
- TPN (Total Parenteral Nutrition)

#### APIs Products (Cephalosporins)

- Sterile Cefotiam HCl
- Sterile Cefmenoxime HCl
- Cefozopran HCl

#### Finished Products (Cephalosporins)

- Banan Tab & Dry Syr. (Cefpodoxime Proxetil)

## Main Products



|                 | Product (Ingredient/Formulation)  | Indication & Use  | Product Image |
|-----------------|---|---|---------------|
| NCE             | <b>K-CAB</b> (Tegoprazan)   | GERD, EE, NERD, GU, H. Pylori   |               |
| FDC             | <b>Exone-A Tab.</b> (Amlodipine+Valsartan+Atorvastatin)   | Hypertension with dyslipidemia  | To be added   |
|                 | <b>Exone-R Tab.</b> (Amlodipine+Valsartan+Rosuvastatin)   | Hypertension with dyslipidemia  |               |
|                 | <b>Exone Tab.</b> (Amlodipine+Valsartan)  | Hypertension  |               |
|                 | <b>Atomet XR Tab.</b> (Atorvastatin+Metformin)  | Type2 Diabetes with Hyperlipidemia  |               |
|                 | <b>Machkhan Tab.</b> (Candesartan+Amlodipine)   | Hypertension  |               |
|                 | <b>Rovazet Tab.</b> (Ezetimibe+Rosuvastatin)  | Hyperlipidemia<br>Primary hypercholesterinemia  |               |
| Antibiotics     | <b>Closone Cap.</b> (Clopidogrel+Aspirin)   | Atherosclerosis, thromboembolism  |               |
|                 | <b>Cinezolid I.V. solution bag</b> (Linezolid)  | Vancomycin-resistant Enterococcus faecium infections  |               |
|                 | <b>Moveloxin I.V. solution bag</b> (Moxifloxacin)   | Acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community acquired pneumonia and so on |               |
|                 | <b>Citopcin I.V. Solution bag</b> (Ciprofloxacin)   | Infections caused by microorganism  |               |
|                 | <b>Levotopcin I.V. Solution bag</b> (Levofloxacin)  | Infections caused by susceptible microorganism  |               |
|                 | <b>Vancorin Inj.</b> (Vancomycin)   | Serious, life-threatening infections by gram-positive bacteria  |               |
|                 | <b>Tapocin Inj.</b> (Teicoplanin)   | Serious infections by gram-positive bacteria  |               |
|                 | <b>Enteone Tab.</b> (Entecavir)   | Hepatitis B virus   |               |
|                 | <b>Calmtop RTU Inj.</b> (Irinotecan)  | Colorectal cancer   |               |
|                 | <b>Pemta RTU Inj.</b> (Pemetrexed)  | Pleural mesothelioma and non-small cell lung cancer   |               |
| Anti-Cancer     | <b>Tarceone Tab.</b> (Erlotinib)  | Non-small cell lung cancer and pancreatic cancer  |               |
|                 | <b>Carevec Tab.</b> (Imatinib)  | Chronic myelogenous leukemia and acute lymphocytic leukemia   |               |
| Antidepressants | <b>Silenor Tab.</b> (Doxepine)  | Insomnia, <b>Non-addictive</b> and helps staying asleep longer  |               |
| Urology         | <b>Vesistar Tab.</b> (Solifenacin)  | Overactive bladder  |               |
| TPN / PN        | <b>Omapone Peripheral/Central Inj.</b> (Lipid, Amino acids and Glucose)<br><b>Omapone Lipid Inj.</b> (Soybean, MCT, fish oil) | Emulsion for intravenous nutrition  |               |
| Biologicals     | <b>Epokine Inj.</b> (rh-EPO)  | Anemia of hemodialysis patients with end-stage renal disease  |               |

FDC : Fixed Dose Combination TPN : Total Parenteral Nutrition PN : Parenteral Nutrition MCT : Medium-Chain Triglycerides

|        | Product (Ingredient/Formulation)  | Indication & Use  | Product Image |
|--------|---|---|---------------|
| Drinks | <b>CONDITION CEO</b><br><b>CONDITION LADY</b> (Hyaluronic acid)   | Anti-hangover drink<br>※General Beverage                    |               |
|        | <b>HONGSAMJIN</b> (4years old red ginseng extract)<br><b>HONGSAMJIN GOLD</b> (6years old red ginseng extract) | Red Ginseng drink   |               |
|        | <b>HUTGAESOO</b> (Oriental raisin tree fruit extract concentrate)   | Natural oriental raisin tea with zero calories and caffeine |               |

## R&D Pipeline



|          | Pipeline  | Mechanism                         | Indication                                 | Development (Schedule)              | Target Launch |
|----------|---|-----------------------------------|--|-------------------------------------|---------------|
| GERD     | <b>K-CAB Tab.</b> (Tegoprazan)                          | P-CAB                             | GERD, EE, NERD, GU, H. Pylori              | Launched                            |               |
|          |   |                                   | Maintenance Treatment                      | P3 (2023)                           |               |
| RA       | <b>IN-A002</b>  | JAK inhibitor                     | Rheumatoid Arthritis                       | P1 (2021)                           | -             |
| Vaccines | <b>IN-B001</b>  | CVA16+EV71                        | Hand, Foot and Mouth Disease               | P1 (2021)                           | 2030          |
| IMD      | <b>Exone-A Tab.</b> (Amlodipine+Valsartan+Atorvastatin) | CCB+ARB+HMG-CoA                   | Hypertension, Dyslipidemia                 | P3 (2020)                           | 2020          |
|          | <b>IN-C009</b> (Dapagliflozin+Linagliptin)              | SGLT2+DPP4                        | Diabetes                                   | P1 (2021)                           | 2024          |
|          | <b>IN-C011</b> (Dapagliflozin+Metformin)                | SGLT2                             | Diabetes                                   | PK (2020)                           | 2023          |
| TPN      | <b>IN-C006</b>  | Feeding of specialist nutritional | Total Parenteral Nutrition new Composition | Preclinical (2021)                  | 2022          |
| Generic  | <b>Ticagrelor</b>                                       | P2Y12 receptor inhibitor          | Antithrombotics                            | Comparative Dissolution Test (2020) | 2021          |
|          | <b>Cilostazol SR</b>                                    | PDE3 inhibitor                    |  | BE (2020)                           | 2022          |
|          | <b>Dapagliflozin</b>                                    | SGLT2 inhibitor                   | Diabetes                                   | PK (2020)                           | 2023          |

PC : Preclinical Studies IMD : Incrementally Modified Drug